報價延遲最少15分鐘:2026/04/26 04:11 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.27 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.33/-0.56
|
|
企業價值
109.11M
|
| 資產負債 |
|
每股賬面淨值
1.28
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
90.50M
|
|
每股收益
1.53
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic andeither do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA. |
